Drug Profile
PLX 200
Alternative Names: PLX-200Latest Information Update: 03 Jan 2024
Price :
$50
*
At a glance
- Originator Polaryx Therapeutics
- Class Anti-inflammatories; Neuroprotectants; Small molecules
- Mechanism of Action Apoptosis inhibitors; Peroxisome proliferator-activated receptor alpha agonists; Retinoid X receptor agonists; Tripeptidyl-peptidase 1 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Neuronal ceroid lipofuscinosis
- Phase I Globoid cell leukodystrophy; Tay-Sachs disease
Most Recent Events
- 03 Jan 2024 Phase-I clinical trials in Globoid cell leukodystrophy (PO) (Polaryx Therapeutics pipeline, January 2024) (Polaryx Therapeutics pipeline, January 2023)
- 03 Jan 2024 Phase-I clinical trials in Tay-Sachs disease (PO) (Polaryx Therapeutics pipeline, January 2024) (Polaryx Therapeutics pipeline, January 2023)
- 07 Sep 2021 PLX 200 receives Orphan Drug status for Globoid cell leukodystrophy in USA